Drug Profile
PIN 2
Alternative Names: PIN 2; Precision Immune Stimulants-2Latest Information Update: 28 Jan 2021
Price :
$50
*
At a glance
- Originator PIN Pharma Inc
- Class Antineoplastics; Peptides
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Jan 2021 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease) in Australia (IV)
- 01 Jun 2019 Pharmacokinetic and safety data from a phase I trial in Solid tumours presented at the 55th Annual Meeting of the American Society of Clinical Oncology (ASCO-2019)
- 06 May 2019 Pharmacodynamics data from a preclinical studies in Solid tumours released by PIN Pharma